Mitsubishi UFJ Asset Management Co. Ltd. Buys 685,111 Shares of Pfizer Inc. $PFE

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,081,382 shares of the biopharmaceutical company's stock after buying an additional 685,111 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.21% of Pfizer worth $304,209,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. AssuredPartners Investment Advisors LLC lifted its stake in Pfizer by 8.6% during the 4th quarter. AssuredPartners Investment Advisors LLC now owns 51,217 shares of the biopharmaceutical company's stock valued at $1,275,000 after acquiring an additional 4,075 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Pfizer by 0.7% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 825,850 shares of the biopharmaceutical company's stock valued at $20,564,000 after purchasing an additional 5,501 shares during the last quarter. SBI Securities Co. Ltd. lifted its position in shares of Pfizer by 8.0% during the fourth quarter. SBI Securities Co. Ltd. now owns 550,371 shares of the biopharmaceutical company's stock valued at $13,704,000 after purchasing an additional 40,920 shares in the last quarter. Garner Asset Management Corp purchased a new position in Pfizer during the fourth quarter worth about $42,000. Finally, McIlrath & Eck LLC boosted its holdings in Pfizer by 43.8% during the fourth quarter. McIlrath & Eck LLC now owns 6,186 shares of the biopharmaceutical company's stock worth $154,000 after purchasing an additional 1,883 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 results beat expectations: Pfizer reported $14.45B in revenue and $0.75 EPS, topping Street estimates as growth from recently launched and acquired products (notably Eliquis and cancer drugs) offset declines in COVID sales. Pfizer beats Q1 profit estimates on strong demand for blood thinner Eliquis (Reuters)
• Positive Sentiment: Pipeline and M&A support longer-term growth: Management highlighted pipeline progress and the strategic Metsera acquisition (obesity) as key to offsetting legacy declines and to drive post‑2028 growth. Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth (CNBC)
• Positive Sentiment: Legal and patent developments extend revenue visibility: A patent settlement around Vyndamax and recent favorable rulings (including COVID‑vaccine related wins) were cited as reshaping the company’s post‑2028 revenue outlook. Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View (Benzinga)
• Positive Sentiment: New FDA approval: Pfizer (with Arvinas) won approval for VEPPANU, a first‑of‑its‑kind therapy for ESR1‑mutated advanced breast cancer, adding a near‑term commercial product. Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy (Benzinga)
• Neutral Sentiment: Guidance reiterated but with modest gaps vs. consensus: Pfizer reaffirmed FY‑2026 guidance (EPS $2.80–3.00; revenue $59.5B–62.5B), roughly in line but the EPS range is slightly conservative versus consensus, leaving limited upside in near‑term estimates. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (BusinessWire)
• Negative Sentiment: Higher R&D and expense pressure: Increased R&D spending weighed on profit, producing lower adjusted margins vs. the prior year and signaling near‑term profit pressure as the company invests in pipeline. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending (WSJ)
• Negative Sentiment: Mixed market reaction and skepticism: Some analysts call the quarter “mild” — beats were offset by conservative guidance and margin pressures, so the report may not satisfy investors focused on near‑term sales acceleration. Why Pfizer's 'Mild' First-Quarter Report Likely Won't Satisfy Skeptics (Investors.com)

Pfizer Trading Up 0.5%

Shares of PFE stock opened at $26.42 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market cap of $150.24 billion, a P/E ratio of 19.43 and a beta of 0.35. The company has a 50 day moving average of $27.17 and a 200-day moving average of $26.13. Pfizer Inc. has a 12-month low of $21.97 and a 12-month high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the company earned $0.92 earnings per share. Pfizer's revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date is Friday, May 8th. Pfizer's payout ratio is currently 126.47%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on PFE shares. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an "outperform" rating and a $33.00 target price on the stock. HSBC increased their price target on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Daiwa Securities Group cut Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective on the stock. in a research report on Thursday, February 12th. UBS Group upped their price objective on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Monday, April 13th. Finally, Zacks Research upgraded Pfizer from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus price target of $28.74.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.